ACRS
Aclaris Therapeutics Stock Analysis
AI Rating
- Quality3/10
- Growth↑ 6/10
- Value↓ 0/10
ACRS Growth
- Revenue Y/Y↓ -58.19%
- EPS Y/Y↑ 69.01%
- FCF Y/Y↓ -133.83%
ACRS Profitability
- Gross margin ↓ 6.90%
- EPS margin↓ -829.60%
- ROIC 5Y↓ -67.96%
ACRS Risk
- Debt / Equity↓ 0.0
- Debt / FCF↓ 0.0
- Interest coverage↑ 999.0
Aclaris Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.